Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.71 USD
+0.02 (0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.70 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Atea Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 578 | 647 | 764 | 856 | 22 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 14 | 8 | 8 | 0 |
Total Current Assets | 590 | 661 | 772 | 863 | 22 |
Net Property & Equipment | 1 | 2 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 0 | 0 | 0 |
Total Assets | 595 | 667 | 773 | 864 | 22 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 5 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 27 | 15 | 52 | 14 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 301 | 0 |
Total Current Liabilities | 32 | 18 | 57 | 316 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 5 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 6 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 40 | 26 | 63 | 316 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 69 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 751 | 701 | 654 | 613 | 5 |
Retained Earnings | -196 | -60 | 56 | -65 | -54 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 555 | 641 | 710 | 548 | 20 |
Total Liabilities & Shareholder's Equity | 595 | 667 | 773 | 864 | 22 |
Total Common Equity | 555 | 641 | 710 | 548 | -50 |
Shares Outstanding | 83.40 | 83.20 | 83.10 | 82.60 | NA |
Book Value Per Share | 6.66 | 7.70 | 8.54 | 6.63 | 0.00 |
Fiscal Year End for Atea Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 578 | 595 | 608 | 620 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 12 | 8 | 13 | 12 |
Total Current Assets | NA | 590 | 603 | 621 | 632 |
Net Property & Equipment | NA | 1 | 1 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 2 | 2 |
Total Assets | NA | 595 | 608 | 626 | 638 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 0 | 4 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 27 | 18 | 11 | 11 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 32 | 19 | 16 | 12 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 6 | 6 | 5 | 5 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 40 | 26 | 24 | 20 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 751 | 739 | 726 | 714 |
Retained Earnings | NA | -196 | -157 | -124 | -95 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 555 | 582 | 602 | 618 |
Total Liabilities & Shareholder's Equity | NA | 595 | 608 | 626 | 638 |
Total Common Equity | 0 | 555 | 582 | 602 | 618 |
Shares Outstanding | 84.10 | 83.40 | 83.40 | 83.40 | 83.40 |
Book Value Per Share | 0.00 | 6.66 | 6.98 | 7.22 | 7.41 |